Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track QNCX with free AI briefings, catalyst countdowns, and dilution alerts.

QNCX · IRulya Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

New ticker. IRulya Therapeutics now trades under the ticker IRLA.
$230.4M Cash on Hand
52.1mo Cash Runway
Follow QNCX by email Get an email when QNCX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about QNCX, unsubscribe in one click. Privacy

📣 What QNCX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Apilimod Mesylate COVID-19 Disease Phase 2 · NCT04446377 Completed
LAM-001 Bronchiolitis Obliterans Syndrome Phase 2 · NCT06018766 Recruiting
Apilimod Dimesylate Capsule (LAM-002A) Amyotrophic Lateral Sclerosis Phase 2 · NCT05163886 Completed
Open Label LAM-003 Oncology Phase 1 · NCT03426605 Completed

Also used in these trials (approved or third-party drugs, not QNCX's own candidates): Atezolizumab, Rituximab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

QNCX holds $230.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $13.3M/quarter from operations, an estimated runway of 52.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when QNCX files for a raise →

👥 Who Owns QNCX

Insiders 14.8% Other 5%+ holders 19.5% Institutions 65.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
GROUP ONE TRADING LLC Institution (13G, 5%+) 5,942,906 54.82% 2026-02-28
Millennium Management LLC 5%+ holder (13G) 1,403,697 12.95% 2026-06-04
Dirk Thye
CEO and CMO, Director · +2.35M options
Insider 994,885 9.18% 2025-12-10
Perceptive Advisors LLC Institution (13G, 5%+) 912,853 8.42% 2026-10-06
SilverArc Capital Management, LLC Institution (13G, 5%+) 880,255 8.12% 2026-09-30
James B. Tananbaum 5%+ holder (13G) 652,039 6.01% 2026-10-06
Brendan Hannah
CBO, COO & CCO · +1.10M options
Insider 361,827 3.34% 2025-12-05
Charles S. Ryan
President · +507,548 options
Insider 130,009 1.20% 2025-06-18
Cormorant Asset Management, LP Institution (13G, 5%+) 108,029 1.00% 2026-06-30
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 97,699 0.90% 2026-06-30
Ikarian Capital, LLC Institution (13G, 5%+) 91,789 0.85% 2026-06-30
John Militello
Chief Financial Officer
Insider 80,000 0.74% 2026-11-09

Share count 10,841,470 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full QNCX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QNCX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.